Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
AdAlta Ltd. ( (AU:1AD) ) has issued an announcement.
AdAlta Ltd has announced a change in the interests of its director, Tim Oldham, involving the disposal of 1,200,000 unlisted options and 1,396,999 performance rights, while acquiring 1,396,999 ordinary shares. This change reflects a strategic adjustment in the director’s holdings, potentially impacting the company’s stock dynamics and signaling confidence in its future performance.
The most recent analyst rating on (AU:1AD) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on AdAlta Ltd. stock, see the AU:1AD Stock Forecast page.
More about AdAlta Ltd.
AdAlta Ltd is a biotechnology company focused on developing innovative therapies using its proprietary i-body technology. The company primarily targets unmet needs in the healthcare industry, particularly in the areas of fibrosis and cancer treatment.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$6.62M
For detailed information about 1AD stock, go to TipRanks’ Stock Analysis page.